Astellas Zolbetuximab Trial Results Cement CLDN18.2 as Pan-Cancer Biomarker

Astellas Pharma has announced positive results from a large Phase III trial (SPOTLIGHT) of zolbetuximab in CLDN18.2-positive and HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.